Regulatory T Cells in Gynecologic Cancer

Overview

Journal MOJ Immunol

Date 2019 Jan 15

PMID 30637330

Citations 14

Authors

Yang Ou

Martin J Cannon

Mayumi Nakagawa

Affiliations

Soon will be listed here.

Abstract

Increasing evidence supports that regulatory T cells (Tregs) within the tumor, tumor draining lymph nodes, ascites and peripheral blood of patients with cancer are associated with poor prognosis. Tregs are important mediators of active immune evasion in cancer. In this review, the potential mechanisms of Treg actions and the roles of Tregs specifically in the tumor microenvironment derived from three types of gynecological cancers, cervical, vulvar and ovarian, are described. The correlations between Tregs and clinical immunotherapeutic study outcomes are discussed. Successful modulation of Tregs would likely have significant impact on the effectiveness of immunotherapeutic treatments in cancer patients.

Citing Articles

A role of gut microbiota metabolites in HLA-E and NKG2 blockage immunotherapy against tumors: new insights for clinical application.

Cheng W, Zhu N, Wang J, Yang R Front Immunol. 2024; 15:1331518.

PMID: 39229258 PMC: 11368731. DOI: 10.3389/fimmu.2024.1331518.

Brachytherapy for targeting the immune system in cervical cancer patients.

Linares I, Berenguer Frances M, Canas R, Najjari D, Gutierrez C, Marin S BMC Immunol. 2023; 24(1):23.

PMID: 37559025 PMC: 10413692. DOI: 10.1186/s12865-023-00559-y.

Pretreatment Immune Status, Predicts Response to Definite Chemo Radiotherapy in Advanced Stages of Cervical Cancer Patients.

Garg S, Shekhawat U, Vohra R, Gupta R J Obstet Gynaecol India. 2022; 72(Suppl 1):319-325.

PMID: 35928063 PMC: 9343502. DOI: 10.1007/s13224-022-01624-z.

Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer.

Mu J, Wu Y, Jiang C, Cai L, Li D, Cao J Front Nutr. 2022; 9:809091.

PMID: 35464000 PMC: 9024308. DOI: 10.3389/fnut.2022.809091.

Immunotherapeutic Approaches for Glioblastoma Treatment.

Yaghi N, Gilbert M Biomedicines. 2022; 10(2).

PMID: 35203636 PMC: 8962267. DOI: 10.3390/biomedicines10020427.

References

Lee H, Bautista J, Hsieh C . Thymic and peripheral differentiation of regulatory T cells. Adv Immunol. 2011; 112:25-71. DOI: 10.1016/B978-0-12-387827-4.00002-4. View

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

Joura E, Losch A, Breitenecker G, Leodolter S . Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med. 2000; 45(8):613-5. View

Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P . Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005; 65(12):5020-6. DOI: 10.1158/0008-5472.CAN-04-4043. View

Welters M, Kenter G, Piersma S, Vloon A, Lowik M, Berends-van der Meer D . Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008; 14(1):178-87. DOI: 10.1158/1078-0432.CCR-07-1880. View

Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M . Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol. 2003; 129(9):521-30. DOI: 10.1007/s00432-003-0463-5. View

Hammes L, Tekmal R, Naud P, Edelweiss M, Kirma N, Valente P . Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation. Gynecol Oncol. 2007; 105(1):157-65. DOI: 10.1016/j.ygyno.2006.11.023. View

Levings M, Roncarolo M . T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000; 106(1 Pt 2):S109-12. DOI: 10.1067/mai.2000.106635. View

Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N . CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005; 202(8):1075-85. PMC: 2213209. DOI: 10.1084/jem.20051511. View

10.

Adurthi S, Krishna S, Mukherjee G, Bafna U, Devi U, Jayshree R . Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. Am J Reprod Immunol. 2008; 60(1):55-65. DOI: 10.1111/j.1600-0897.2008.00590.x. View

11.

Hsieh C, Lee H, Lio C . Selection of regulatory T cells in the thymus. Nat Rev Immunol. 2012; 12(3):157-67. DOI: 10.1038/nri3155. View

12.

Dieckmann D, Bruett C, Ploettner H, Lutz M, Schuler G . Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002; 196(2):247-53. PMC: 2193931. DOI: 10.1084/jem.20020642. View

13.

Frazer I, Quinn M, Nicklin J, Tan J, Perrin L, Ng P . Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004; 23(2):172-81. DOI: 10.1016/j.vaccine.2004.05.013. View

14.

van Esch E, van Poelgeest M, Kouwenberg S, Osse E, Trimbos J, Fleuren G . Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. Int J Cancer. 2014; 136(4):E95-106. DOI: 10.1002/ijc.29174. View

15.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

16.

Yao X, Ahmadzadeh M, Lu Y, Liewehr D, Dudley M, Liu F . Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012; 119(24):5688-96. PMC: 3382928. DOI: 10.1182/blood-2011-10-386482. View

17.

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

18.

Puccetti P, Grohmann U . IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007; 7(10):817-23. DOI: 10.1038/nri2163. View

19.

Thornton A, Shevach E . CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998; 188(2):287-96. PMC: 2212461. DOI: 10.1084/jem.188.2.287. View

20.

Cao X, Cai S, Fehniger T, Song J, Collins L, Piwnica-Worms D . Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007; 27(4):635-46. DOI: 10.1016/j.immuni.2007.08.014. View